The Cancer Research of Kansas (CR Kansas) NCORP, formerly the Wichita Community Clinical Oncology (WCCOP), established and funded by the National Cancer Institute (NCI) in 1983, continued in 1987 (for 3 years), in 1990 (for 5 years), in 1995 (for 5 years), in 2000 (for 5 years), in 2005 (for 5 years), and 2010 (for 5 years). The WCCOP was a citywide cooperative program of the two major community hospitals and most of the Wichita oncologists. CR Kansas is a program, which will provide clinical trial access to a large portion ofthe state, including three community hospitals and most of the state's oncologists. Wichita is located n the center of the United States. It has the largest population center between Kansas City, 200 mile to the northeast, Denver, Colorado, 600 miles to the northwest, and Oklahoma City, 160 miles to the south. The presence of the CCOP/NCORP in Wichita brings the benefits of clinical research to patients in Wichita and its catchment area of south central, southwest and northeast Kansas - an ara that would otherwise be underserved because of its remote distance from the larger comprehensive cancer centers. CR Kansas consortium is in the process of developing a collaborative continuum of care that connects CR Kansas and community resources to deliver patient-centered, clinically integrated care for oncology patients, while demonstrating excellence in safety, quality and reducig avoidable costs. This collaboration will develop a coalition between practitioners across the stateof Kansas and Northern Oklahoma, including oncologists, primary care, surgeons, etc., that will provid an overall continuum of care from screening and prevention services through diagnosis, treatment an follow-up. CR Kansas aims to bring the state of Kansas community together in improving the overall f cancer care statewide. The CR Kansas National Community Oncology Research Program plans to continue an annual accrual of 200 credits on treatment protocols and 400 new credits on cancer control protocols using the eight research bases: NRG, SWOG, ECOG-ACRIN, Alliance, Wake Forest, University of Rochester, M.D. Anderson CCOP, SunCoast, as well as the Cancer Trials Support Unit.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Via Christi Regional Medical Center
United States
Zip Code
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91
Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80

Showing the most recent 10 out of 22 publications